BioWorld Asia

April 20, 2011

Circassia Lands 3rd Largest Biotech Funding in Europe

LONDON – Circassia Ltd. claimed the third largest funding round by a European biotech in the past 15 years, raising £60 million (US$98 million) in a fourth round. (BioWorld International) Read More

Actelion Readies for Ambush; Gets BB Biotech Backing

Fish Oil Drug Cuts Triglycerides in Second Phase III; NDA in 3Q

Potential $285M: Ipsen and Active Biotech in TASQ Deal

Insight into Antidepressant Action Yields Drug Target

4SC in $192M Agreement for Japan Rights to Resminostat

Galapagos Drops Its Lead Program in Rheumatoid Arthritis

Nabriva Gets Phase II Data for I.V. Pleuromutilin Antibiotic

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...